A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis
Launched by ABBVIE · Mar 13, 2014
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Radiographic knee osteoarthritis with Kellgren-Lawrence Grade 2 or 3
- • 2. Body Mass Index (BMI) 18-34 kg/m2
- • 3. One or more clinical signs and symptoms of active inflammation in the index knee
- Exclusion Criteria:
- • 1. History of allergic reaction to any constituents of the study drug, or to any Immunoglobulin G (IgG)-containing product
- • 2. History of anaphylactic reaction to any agent
- • 3. Significant trauma or surgery to the index knee
- • 4. Severe knee malalignment
- • 5. Any uncontrolled medical illness or an unstable treatment or therapy
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Marc Levesque, MD
Study Chair
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials